

# Mette Vesterhus

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7895791/publications.pdf>

Version: 2024-02-01

57  
papers

2,411  
citations

218677

26  
h-index

206112

48  
g-index

59  
all docs

59  
docs citations

59  
times ranked

3428  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact on follow-up strategies in patients with primary sclerosing cholangitis. <i>Liver International</i> , 2023, 43, 127-138.	3.9	15
2	Liver Elastography in Healthy Children Using Three Different Systems – How Many Measurements Are Necessary?. <i>Ultraschall in Der Medizin</i> , 2022, 43, 488-497.	1.5	2
3	Highly Increased Levels of Inter- $\alpha$ -inhibitor Heavy Chain 4 (ITI4) in Autoimmune Cholestatic Liver Diseases. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 796-802.	1.4	3
4	Reply to: “Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis”. <i>Journal of Hepatology</i> , 2021, 74, 755-756.	3.7	2
5	Comprehensive assessment of ECM turnover using serum biomarkers establishes PBC as a high-turnover autoimmune liver disease. <i>JHEP Reports</i> , 2021, 3, 100178.	4.9	7
6	Associations of neopterin and kynurenine-tryptophan ratio with survival in primary sclerosing cholangitis. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 443-452.	1.5	8
7	Circulating Macrophage Activation Markers Predict Transplant-Free Survival in Patients With Primary Sclerosing Cholangitis. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00315.	2.5	10
8	Controlled Attenuation Parameter in Healthy Individuals Aged 8–70 Years. <i>Ultrasound International Open</i> , 2021, 07, E6-E13.	0.6	1
9	Altered Gut Microbial Metabolism of Essential Nutrients in Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , 2021, 160, 1784-1798.e0.	1.3	69
10	Fluctuating biomarkers in primary sclerosing cholangitis: A longitudinal comparison of alkaline phosphatase, liver stiffness, and ELF. <i>JHEP Reports</i> , 2021, 3, 100328.	4.9	8
11	Primary Sclerosing Cholangitis Risk Estimate Tool (PREsTo) Predicts Outcomes of the Disease: A Derivation and Validation Study Using Machine Learning. <i>Hepatology</i> , 2020, 71, 214-224.	7.3	90
12	Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group. <i>Journal of Hepatology</i> , 2020, 73, 1496-1506.	3.7	55
13	Point Shear Wave Elastography and the Effect of Physical Exercise, Alcohol Consumption, and Respiration in Healthy Adults. <i>Ultrasound International Open</i> , 2020, 06, E54-E61.	0.6	1
14	Liver Elastography in Primary Sclerosing Cholangitis Patients Using Three Different Scanner Systems. <i>Ultrasound in Medicine and Biology</i> , 2020, 46, 1854-1864.	1.5	5
15	Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2295-2304.e2.	4.4	18
16	Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities. <i>Journal of Gastroenterology</i> , 2020, 55, 588-614.	5.1	49
17	THU-002-Macrophage activation marker neopterin predicts liver transplantation-free survival in primary sclerosing cholangitis. <i>Journal of Hepatology</i> , 2019, 70, e161.	3.7	0
18	Autotaxin activity predicts transplant-free survival in primary sclerosing cholangitis. <i>Scientific Reports</i> , 2019, 9, 8450.	3.3	8

#	ARTICLE	IF	CITATIONS
19	Cholangiocarcinoma is associated with a raised enhanced liver fibrosis score independent of primary sclerosing cholangitis. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13088.	3.4	14
20	Normal Liver Stiffness Values in Children. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2019, 68, 706-712.	1.8	42
21	Circulating markers of gut barrier function associated with disease severity in primary sclerosing cholangitis. <i>Liver International</i> , 2019, 39, 371-381.	3.9	51
22	Assessing Liver Stiffness by 2-D Shear Wave Elastography in a Healthy Cohort. <i>Ultrasound in Medicine and Biology</i> , 2018, 44, 332-341.	1.5	28
23	Liver elasticity in healthy individuals by two novel shear-wave elastography systemsâ€”Comparison by age, gender, BMI and number of measurements. <i>PLoS ONE</i> , 2018, 13, e0203486.	2.5	37
24	Serological markers of extracellular matrix remodeling predict transplant-free survival in primary sclerosing cholangitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 179-189.	3.7	28
25	Normal liver elasticity values in a healthy population, by age and gender, for two novel elastography systems. <i>Journal of Hepatology</i> , 2018, 68, S645-S646.	3.7	0
26	Repeatability of shear wave elastography in liver fibrosis phantomsâ€”Evaluation of five different systems. <i>PLoS ONE</i> , 2018, 13, e0189671.	2.5	37
27	The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. <i>Gut</i> , 2017, 66, 611-619.	12.1	308
28	Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study. <i>Liver International</i> , 2017, 37, 1554-1561.	3.9	54
29	Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis. <i>Journal of Hepatology</i> , 2017, 66, 1214-1222.	3.7	51
30	Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis. <i>Gut</i> , 2017, 66, 137-144.	12.1	59
31	Elevated trimethylamineâ€”oxide (TMAO) is associated with poor prognosis in primary sclerosing cholangitis patients with normal liver function. <i>United European Gastroenterology Journal</i> , 2017, 5, 532-541.	3.8	20
32	Primary sclerosing cholangitis â€” a comprehensive review. <i>Journal of Hepatology</i> , 2017, 67, 1298-1323.	3.7	538
33	Antineutrophil antibodies define clinical and genetic subgroups in primary sclerosing cholangitis. <i>Liver International</i> , 2017, 37, 458-465.	3.9	28
34	Elevated interleukinâ€”8 in bile of patients with primary sclerosing cholangitis. <i>Liver International</i> , 2016, 36, 1370-1377.	3.9	34
35	Biliary Tract Cancer with or without Primary Sclerosing Cholangitis is Associated with a Raised Enhanced Liver Fibrosis Test Result Compared with PSC Alone. <i>Journal of Hepatology</i> , 2016, 64, S722-S723.	3.7	0
36	Serological Biomarkers of Extracellular Matrix Remodeling Predict Transplant-Free Survival in Primary Sclerosing Cholangitis Patients. <i>Journal of Hepatology</i> , 2016, 64, S199.	3.7	2

#	ARTICLE	IF	CITATIONS
37	Ultrasound and Point Shear Wave Elastography in Livers of Patients with Primary Sclerosing Cholangitis. <i>Ultrasound in Medicine and Biology</i> , 2016, 42, 2146-2155.	1.5	14
38	In Vitro Comparison of Five Different Elastography Systems for Clinical Applications, Using Strain and Shear Wave Technology. <i>Ultrasound in Medicine and Biology</i> , 2016, 42, 2572-2588.	1.5	37
39	Autoreactive Iga Antibodies against the Pancreatic Major Glycoprotein 2 are Associated with Primary Sclerosing Cholangitis and Related Biliary Tract Cancer. <i>Journal of Hepatology</i> , 2016, 64, S647.	3.7	1
40	Prognostic biomarkers and surrogate end points in PSC. <i>Liver International</i> , 2016, 36, 1748-1751.	3.9	1
41	Altered gut microbiota profile in common variable immunodeficiency associates with levels of lipopolysaccharide and markers of systemic immune activation. <i>Mucosal Immunology</i> , 2016, 9, 1455-1465.	6.0	130
42	PWE-096 Non-invasive assessment of disease severity in primary sclerosing cholangitis (psc): clinical scores, transient elastography (te) and the enhanced liver fibrosis (elf) test: Abstract PWE-096 Table 1. <i>Gut</i> , 2015, 64, A254.1-A254.	12.1	0
43	Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis. <i>Hepatology</i> , 2015, 62, 188-197.	7.3	106
44	O082 : The gut microbiota in primary sclerosing cholangitis differs from that of healthy controls and ulcerative colitis patients without biliary disease. <i>Journal of Hepatology</i> , 2015, 62, S231-S232.	3.7	1
45	P1174 : Microbiota-dependent marker trimethylamine-N-oxide (TMAO) is associated with the severity of primary sclerosing cholangitis. <i>Journal of Hepatology</i> , 2015, 62, S793-S794.	3.7	1
46	Review article: controversies in the management of primary biliary cirrhosis and primary sclerosing cholangitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 282-301.	3.7	75
47	O133 NOVEL PROTEIN MARKERS IDENTIFIED IN BILE AND SERUM ARE ASSOCIATED WITH A DIAGNOSIS OF PRIMARY SCLEROSING CHOLANGITIS, DISEASE SEVERITY, AND TRANSPLANT-FREE SURVIVAL. <i>Journal of Hepatology</i> , 2014, 60, S55-S56.	3.7	1
48	P363 ENHANCED LIVER FIBROSIS SCORE PREDICTS TRANSPLANT-FREE SURVIVAL IN PSC INDEPENDENTLY OF THE MAYO RISK SCORE. <i>Journal of Hepatology</i> , 2014, 60, S188.	3.7	0
49	Carboxyl-Ester Lipase Maturity-Onset Diabetes of the Young Is Associated With Development of Pancreatic Cysts and Upregulated MAPK Signaling in Secretin-Stimulated Duodenal Fluid. <i>Diabetes</i> , 2014, 63, 259-269.	0.6	38
50	Absence of Diabetes and Pancreatic Exocrine Dysfunction in a Transgenic Model of Carboxyl-Ester Lipase-MODY (Maturity-Onset Diabetes of the Young). <i>PLoS ONE</i> , 2013, 8, e60229.	2.5	20
51	The role of pancreatic imaging in monogenic diabetes mellitus. <i>Nature Reviews Endocrinology</i> , 2012, 8, 148-159.	9.6	32
52	Diabetes and Pancreatic Exocrine Dysfunction Due to Mutations in the Carboxyl Ester Lipase Gene-Maturity Onset Diabetes of the Young (CEL-MODY). <i>Journal of Biological Chemistry</i> , 2011, 286, 34593-34605.	3.4	80
53	Pancreatic Function in Carboxyl-Ester Lipase Knockout Mice. <i>Pancreatology</i> , 2010, 10, 467-476.	1.1	26
54	Lack of pancreatic body and tail in HNF1B mutation carriers. <i>Diabetic Medicine</i> , 2008, 25, 782-787.	2.3	98

#	ARTICLE	IF	CITATIONS
55	Pancreatic Exocrine Dysfunction in Maturity-Onset Diabetes of the Young Type 3. <i>Diabetes Care</i> , 2008, 31, 306-310.	8.6	25
56	Neurological Features and Enzyme Therapy in Patients With Endocrine and Exocrine Pancreas Dysfunction Due to <i>CEL</i> Mutations. <i>Diabetes Care</i> , 2008, 31, 1738-1740.	8.6	14
57	Reduced Pancreatic Volume in Hepatocyte Nuclear Factor 1A-Maturity-Onset Diabetes of the Young. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 3505-3509.	3.6	29